• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Company
    • Company Overview
    • Leadership Team
    • Careers
    • Contact Us

    We are dedicated to transforming cardiovascular muscle diseases.

    Learn More

  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious cardiovascular diseases with unmet medical needs.

    Explore our Pipeline

  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten

    Servier Acquires Our Muscular Dystrophy Program

    Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.

    Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.

    Learn more

  • Patients & Families
  • Investors & News
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomeCompanyLeadership Team

Leadership Team & Board of Directors

Experienced Life-science leadership

  • Leadership team
  • Board of directors

Leadership Team

Kevin Koch, Ph.D.

President and Chief Executive Officer

Read Kevin Koch, Ph.D.'s Bio

Alan Russell, Ph.D.

Co-Founder and Chief Scientific Officer

Read Alan Russell, Ph.D.'s Bio

Behrad Derakhshan, Ph.D.

Chief Operating Officer

Read Behrad Derakhshan, Ph.D.'s Bio

Joanne M. Donovan, M.D., Ph.D.

Chief Medical Officer

Read Joanne M. Donovan, M.D., Ph.D.'s Bio

John Moore

General Counsel

Read John Moore's Bio

Michael Nofi

Chief Financial Officer

Read Michael Nofi's Bio

Board of Directors

Peter Thompson, M.D.

Chairman and Co-Founder

Read Peter Thompson, M.D.'s Bio

Laura Brege

Director

Read Laura Brege's Bio

Badreddin Edris, Ph.D.

Director and Co-Founder

Read Badreddin Edris, Ph.D.'s Bio

Jonathan C. Fox, M.D., Ph.D., FACC

Director

Read Jonathan C. Fox, M.D., Ph.D., FACC's Bio

Kevin Koch, Ph.D.

Director

Read Kevin Koch, Ph.D.'s Bio

Christopher Martin

Director

Read Christopher Martin's Bio

Arlene Morris

Director

Read Arlene Morris's Bio

Jon Root, M.D.

Director

Read Jon Root, M.D.'s Bio

Alan Russell, Ph.D.

Director and Co-Founder

Read Alan Russell, Ph.D.'s Bio

Footer

Edgewise Therapeutics
  • Company
  • Science
  • Disease Areas
  • Patients & Families
  • Investors & News

In the Clinic

We are advancing novel precision therapeutics for serious cardiovascular disease.

Explore our pipeline

2026 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations
  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten
  • Patients & Families
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts